HC Wainwright Reiterates “Buy” Rating for Aura Biosciences (NASDAQ:AURA)

HC Wainwright reaffirmed their buy rating on shares of Aura Biosciences (NASDAQ:AURA) in a report released on Monday morning,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright also issued estimates for Aura Biosciences’ Q3 2025 earnings at ($0.47) EPS and FY2027 earnings at ($1.64) EPS.

Separately, Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $23.00.

Aura Biosciences Trading Down 15.4 %

Shares of AURA opened at $5.99 on Monday. Aura Biosciences has a 12-month low of $5.94 and a 12-month high of $12.38. The stock has a market cap of $299.21 million, a P/E ratio of -3.46 and a beta of 0.30. The company has a 50-day moving average of $7.60 and a two-hundred day moving average of $8.64.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). As a group, analysts forecast that Aura Biosciences will post -1.66 EPS for the current fiscal year.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 23,045 shares of company stock worth $177,242. Insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AURA. Wellington Management Group LLP increased its position in Aura Biosciences by 12.6% during the fourth quarter. Wellington Management Group LLP now owns 131,054 shares of the company’s stock worth $1,077,000 after purchasing an additional 14,662 shares during the last quarter. ProShare Advisors LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter valued at $127,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Aura Biosciences by 27.7% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company’s stock worth $1,122,000 after buying an additional 29,618 shares during the last quarter. Ensign Peak Advisors Inc raised its position in shares of Aura Biosciences by 43.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock worth $3,212,000 after buying an additional 118,000 shares during the period. Finally, Deutsche Bank AG boosted its holdings in Aura Biosciences by 56.7% in the fourth quarter. Deutsche Bank AG now owns 44,085 shares of the company’s stock valued at $362,000 after acquiring an additional 15,951 shares during the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.